UK pharma giant AstraZeneca on Monday unveiled another $140 million equity investment in cell and gene therapy partner Cellectis.

AstraZeneca now owns 44% of Cellectis’ share capital and has 30% of the partner’s voting rights. Two AstraZeneca leaders, Alexion CEO Marc Dunoyer and corporate development executive director Tyrell Rivers, are also now on Cellectis’ board.

AstraZeneca’s investment in its Paris-based partner was previously planned, the companies said Monday morning.

In November 2023, AstraZeneca paid $25 million upfront and made an $80 million equity investment in the French and US biotech for a 22% stake. A month later, Cellectis took its CAR-T manufacturing in-house.

Cellectis is using its gene editing technology to find up to 25 targets for AstraZeneca.

The UK pharma can snag worldwide exclusive licenses on up to 10 of those for cell and gene therapies in oncology, immunology and rare diseases. Each of those comes with biobucks in the range of $70 million to $220 million. The higher end is roughly equal to Cellectis’ current market cap of $215 million.

Check out our AAV CDMO service to expedite your gene therapy research
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Future Of Gamma Delta T Cell Therapies

Gamma delta T cell-based immunotherapies have emerged as a promising frontier in cancer treatment and beyond, building on the success of chimeric antigen receptor T-cell (CAR T cell) therapy and expanding on the potential of the immune system as a therapeutic...

read more

Related Services

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.

AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.